<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">39977160</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1606-7916</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6 (nov-dec)</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>Salud publica de Mexico</Title><ISOAbbreviation>Salud Publica Mex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>849</StartPage><EndPage>858</EndPage><MedlinePgn>849-858</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21149/15693</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Describir y analizar experiencias por las que transitan mujeres adolescentes con antecedente de un embarazo e identificar las barreras en la aceptaci&#xf3;n y continuidad de anticoncepci&#xf3;n posevento obst&#xe9;trico (APEO). Material y m&#xe9;todos. An&#xe1;lisis secundario del componente cualitativo de dos estudios mixtos en tres entidades con alta, media y baja proporci&#xf3;n de embarazo adolescente en M&#xe9;xico. Se analizaron 30 entrevistas semiestructuradas con madres adolescentes bajo los principios de la teor&#xed;a fundamentada.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Las barreras que se identificaron son la falta de agencia y empoderamiento de las madres adolescentes para la planeaci&#xf3;n de un embarazo subsecuente; influencia de la pareja y familia; y obst&#xe1;culos institucionales como consejer&#xed;a parcial, seguimiento deficiente, falla t&#xe9;cnica del m&#xe9;todo anticonceptivo, presencia de efectos secundarios y desabasto. Conclusi&#xf3;n. La estrategia de APEO debe considerar las necesidades y barreras espec&#xed;ficas de esta poblaci&#xf3;n para dise&#xf1;ar e implementar intervenciones m&#xe1;s efectivas que permitan ampliar el periodo intergen&#xe9;sico m&#xe1;s all&#xe1; de la adolescencia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Romero-P&#xe9;rez</LastName><ForeName>Irma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>El Colegio Mexiquense A. C. Estado de M&#xe9;xico, M&#xe9;xico.. irmaromeroperez86@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>F&#xe1;tima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>C&#xe1;tedra Conacyt, Direcci&#xf3;n de Salud Reproductiva, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. festrada@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campero</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n de Salud Reproductiva, Centro de Investigaci&#xf3;n en Salud Poblacional, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. lcampero@insp.mx.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Barreras en la aceptaci&#xf3;n y continuidad de la anticoncepci&#xf3;n posevento obst&#xe9;trico: experiencias y perspectivas de madres adolescentes en M&#xe9;xico.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Salud Publica Mex</MedlineTA><NlmUniqueID>0404371</NlmUniqueID><ISSNLinking>0036-3634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088662" MajorTopicYN="Y">Adolescent Mothers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003267" MajorTopicYN="Y">Contraception</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003268" MajorTopicYN="Y">Contraception Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079102" MajorTopicYN="N">Empowerment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011253" MajorTopicYN="Y">Pregnancy in Adolescence</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094422" MajorTopicYN="N">Secondary Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066296" MajorTopicYN="N">Grounded Theory</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>12</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39977160</ArticleId><ArticleId IdType="doi">10.21149/15693</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39625388</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Insights Into the Group of Surgically Resectable But Nonoperable Patients With Colorectal Cancer.</ArticleTitle><Pagination><StartPage>351</StartPage><EndPage>358</EndPage><MedlinePgn>351-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003580</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The incidence of colorectal cancer is expected to increase, particularly among patients with significant frailty and comorbidities. A subgroup of these patients may not be suitable for surgery because of the high risk of postoperative morbidity and mortality.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to characterize the clinical outcomes, management, social status, and survival of patients deemed nonoperable because of comorbidity and/or frailty.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Overall survival was estimated using the Kaplan-Meier method. The Cox proportional-hazards model was used to estimate HRs and 95% CIs for mortality-associated modifiable risk factors.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients diagnosed with resectable colorectal cancer but deemed nonoperable because of comorbidity and/or frailty by a multidisciplinary team between January 1, 2020, and April 30, 2024, were included in this study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was to describe the current population, investigate mortality, and explore mortality-related risk factors in the current population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the study period, 69 of 1667 patients who had colorectal cancer that was potentially resectable but who were deemed nonoperable were included in the study population. The rate of 90-day and 1-year mortality was 20% and 52%, respectively. Three years after the diagnosis, 12% of the patients were alive. At the time of diagnosis, anemia was found in 73% of female patients and 71% of male patients. In addition, 77% of the patients had hypoalbuminemia. Lower albumin levels were associated with poor survival (HR, 0.92; 95% CI, 0.88-0.98; p = 0.007).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective nature and small sample size inherently limit the generalizability of the study findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mortality in the current population was high. However, our findings highlight potential areas for improvement in the management of these patients. See Video Abstract .</AbstractText><AbstractText Label="INFORMACIN SOBRE EL GRUPO DE PACIENTES CON CNCER COLORRECTAL RESECABLES QUIRRGICAMENTE PERO NO OPERABLES" NlmCategory="UNASSIGNED">ANTECEDENTES:Se espera que la incidencia del c&#xe1;ncer colorrectal aumente, en particular entre los pacientes con fragilidad y comorbilidades significativas. Un subgrupo de estos pacientes puede no ser apto para la cirug&#xed;a debido al alto riesgo de morbilidad y mortalidad posoperatorias.OBJETIVO:El objetivo de este estudio fue caracterizar los resultados cl&#xed;nicos, el tratamiento, el estado social y la supervivencia de los pacientes considerados no operables debido a la comorbilidad y/o fragilidad.DISE&#xd1;O:Este fue un estudio de cohorte retrospectivo.ESTABLECIMIENTOS:La supervivencia general se estim&#xf3; utilizando el m&#xe9;todo de Kaplan-Meier. Se utiliz&#xf3; el modelo de riesgos proporcionales de Cox para estimar los cocientes de riesgo y los intervalos de confianza del 95% para los factores de riesgo modificables asociados a la mortalidad.PACIENTES:Se incluyeron en este estudio pacientes diagnosticados con c&#xe1;ncer colorrectal resecable pero considerados no operables debido a la comorbilidad y/o fragilidad por un equipo multidisciplinario entre el 1 de enero de 2020 y el 30 de abril de 2024.PRINCIPALES MEDIDAS DE RESULTADOS:El resultado primario fue describir la poblaci&#xf3;n actual, investigar la mortalidad y explorar los factores de riesgo relacionados con la mortalidad en esta poblaci&#xf3;n.RESULTADOS:Durante el per&#xed;odo del estudio, 69 de 1667 pacientes eran potencialmente resecables pero se los consider&#xf3; no operables y se los incluy&#xf3; en la poblaci&#xf3;n del estudio. La tasa de mortalidad a los 90 d&#xed;as y al a&#xf1;o fue del 20% y del 52%, respectivamente. Tres a&#xf1;os despu&#xe9;s del diagn&#xf3;stico, el 12% de los pacientes estaban vivos. En el momento del diagn&#xf3;stico, se encontr&#xf3; anemia en el 73% de las pacientes femeninas y en el 71% de los pacientes masculinos. Adem&#xe1;s, el 77% de los pacientes ten&#xed;an hipoalbuminemia. Los niveles m&#xe1;s bajos de alb&#xfa;mina se asociaron con una supervivencia deficiente, &#xed;ndice de riesgo de 0,92 (intervalo de confianza del 95%: 0,88-0,98, p = 0,007).LIMITACIONES:La naturaleza retrospectiva y el peque&#xf1;o tama&#xf1;o de la muestra limitan inherentemente la generalizaci&#xf3;n de los hallazgos del estudio.CONCLUSIONES:La mortalidad en la poblaci&#xf3;n actual fue alta. Sin embargo, nuestros hallazgos resaltan &#xe1;reas potenciales para mejoras en el manejo de estos pacientes. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ose</LastName><ForeName>Ilze</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7018-9414</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orhan</LastName><ForeName>Adile</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eraslan</LastName><ForeName>Sule</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Enise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandersen</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Righult</LastName><ForeName>Angelina Astrid</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayhan</LastName><ForeName>Emine Ceren</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Amalie Thomsen</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saqi</LastName><ForeName>Ida Kolukisa</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Colorectal Cancer Group, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073496" MajorTopicYN="Y">Frailty</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39625388</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003580</ArticleId><ArticleId IdType="pii">00003453-990000000-00816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;249.</Citation></Reference><Reference><Citation>eurostat. Statistics Explained. Ageing Europe&#x2013;statistics on population developments. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Ageing_Europe_-_statistics_on_population_developments#Older_people_.E2.80.94_population_overview . Accessed June 10, 2024.</Citation></Reference><Reference><Citation>Ose I, Rosen AW, Br&#xe4;uner K, et al. The association of postoperative morbidity and age on 5-year survival after colorectal surgery in the elderly population: a nationwide cohort study. Colorectal Dis. 2024;26:899&#x2013;915.</Citation></Reference><Reference><Citation>Van Walree IC, Scheepers E, van Huis-Tanja L, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriatr Oncol. 2019;10:847&#x2013;858.</Citation></Reference><Reference><Citation>Bojesen RD, Dalton SO, Skou ST, et al. Preoperative multimodal prehabilitation before elective colorectal cancer surgery in patients with WHO performance status I or II: randomized clinical trial. BJS Open. 2023;7:zrad134.</Citation></Reference><Reference><Citation>Heger P, Probst P, Wiskemann J, Steindorf K, Diener MK, Mihaljevic AL. A systematic review and meta-analysis of physical exercise prehabilitation in major abdominal surgery (PROSPERO 2017 CRD42017080366). J Gastrointest Surg. 2020;24:1375&#x2013;1385.</Citation></Reference><Reference><Citation>Brierley J, Gospodarowicz MD, Wittekind CT. Oesophagus and oesophagogastric junction. In: Brierley J, Gospodarowicz MD, Wittekind CT, eds. TNM Classification of Malignant Tumors International Union Against Cancer. 8th ed. Oxford, England: Wiley; 2017:57&#x2013;62.</Citation></Reference><Reference><Citation>Kopp VJ. Use of the American Society of Anesthesiologists physical status classification system in research. Anesth Analg. 2013;117:752.</Citation></Reference><Reference><Citation>Azam F, Latif MF, Farooq A, et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019;12:728&#x2013;736.</Citation></Reference><Reference><Citation>Domenica Cappellini M, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging? Semin Hematol. 2015;52:261&#x2013;269.</Citation></Reference><Reference><Citation>The Danish Colorectal Cancer Group. Klinisk Retningslinjer &#x2502;Kraeft DCCG version 2.0. www.dccg.dk/retningslinjer . Accessed June 15, 2024.</Citation></Reference><Reference><Citation>Hardt J, Pilz L, Magdeburg J, Kienle P, Post S, Magdeburg R. Preoperative hypoalbuminemia is an independent risk factor for increased high-grade morbidity after elective rectal cancer resection. Int J Colorectal Dis. 2017;32:1439&#x2013;1446.</Citation></Reference><Reference><Citation>Jerath A, Austin PC, Wijeysundera DN. Days alive and out of hospital: validation of a patient-centered outcome for perioperative medicine. Anesthesiology. 2019;131:84&#x2013;93.</Citation></Reference><Reference><Citation>Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343&#x2013;346.</Citation></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457.</Citation></Reference><Reference><Citation>Lidder PG, Sanders G, Whitehead E, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery&#x2014;a prospective, randomised, controlled trial. Ann R Coll Surg Engl. 2007;89:418&#x2013;421.</Citation></Reference><Reference><Citation>Wilson MJ, van Haaren M, Harlaar JJ, et al. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: a systematic review and meta-analysis. Surg Oncol. 2017;26:96&#x2013;104.</Citation></Reference><Reference><Citation>Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011&#x2013;1023.</Citation></Reference><Reference><Citation>Hu WH, Eisenstein S, Parry L, Ramamoorthy S. Preoperative malnutrition with mild hypoalbuminemia associated with postoperative mortality and morbidity of colorectal cancer: a propensity score matching study. Nutr J. 2019;18:33.</Citation></Reference><Reference><Citation>Haskins IN, Baginsky M, Amdur RL, Agarwal S. Preoperative hypoalbuminemia is associated with worse outcomes in colon cancer patients. Clin Nutr. 2017;36:1333&#x2013;1338.</Citation></Reference><Reference><Citation>Mullen MG, Michaels AD, Mehaffey HJ, et al. Risk associated with complications and mortality after urgent surgery vs elective and emergency surgery: implications for defining &#x201c;quality&#x201d; and reporting outcomes for urgent surgery. JAMA Surg. 2017;152:768&#x2013;774.</Citation></Reference><Reference><Citation>Leicher LW, Huisman JF, Van Grevenstein WMU, et al. Colonoscopic-assisted laparoscopic wedge resection for colonic lesions: a prospective multicenter cohort study (LIMERIC-Study). Ann Surg. 2022;275:933&#x2013;939.</Citation></Reference><Reference><Citation>Zwager LW, Bastiaansen BAJ, Van Der Spek BW, et al.; Dutch eFTR Group. Endoscopic full-thickness resection of T1 colorectal cancers: a retrospective analysis from a multicenter Dutch eFTR registry. Endoscopy. 2022;54:475&#x2013;485.</Citation></Reference><Reference><Citation>Hartwig MFS, Bulut M, Ravn-Eriksen J, et al. Combined endoscopic and laparoscopic surgery (CELS) for early colon cancer in high-risk patients. Surg Endosc. 2023;37:8511&#x2013;8521.</Citation></Reference><Reference><Citation>Ha RK, Park B, Han KS, et al. Subpopulation analysis of survival in high-risk T1 colorectal cancer: surgery versus endoscopic resection only. Gastrointest Endosc. 2022;96:1036&#x2013;1046.e1.</Citation></Reference><Reference><Citation>Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer. 2020;1874:188447.</Citation></Reference><Reference><Citation>Andr&#xe9; T, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability&#x2013;high advanced colorectal cancer. N Engl J Med. 2020;383:2207&#x2013;2218.</Citation></Reference><Reference><Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566&#x2013;576.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38408871</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Clinical Utility of Laser Speckle Contrast Imaging and Real-Time Quantification of Bowel Perfusion in Minimally Invasive Left-Sided Colorectal Resections.</ArticleTitle><Pagination><StartPage>850</StartPage><EndPage>859</EndPage><MedlinePgn>850-859</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003098</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left-sided colorectal surgery demonstrates high anastomotic leak rates, with tissue ischemia thought to influence outcomes. Indocyanine green is commonly used for perfusion assessment, but evidence remains mixed for whether it reduces colorectal anastomotic leaks. Laser speckle contrast imaging provides dye-free perfusion assessment in real-time through perfusion heat maps and quantification.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study investigates the efficacy of advanced visualization (indocyanine green versus laser speckle contrast imaging), perfusion assessment, and utility of laser speckle perfusion quantification in determining ischemic margins.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective intervention group using advanced visualization with case-matched, retrospective control group.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Single academic medical center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Forty adult patients undergoing elective, minimally invasive, left-sided colorectal surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Intraoperative perfusion assessment using white light imaging and advanced visualization at 3 time points: T1-proximal colon after devascularization, before transection, T2-proximal/distal colon before anastomosis, and T3-completed anastomosis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Intraoperative indication of ischemic line of demarcation before resection under each visualization method, surgical decision change using advanced visualization, post hoc laser speckle perfusion quantification of colorectal tissue, and 30-day postoperative outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Advanced visualization changed surgical decision-making in 17.5% of cases. For cases in which surgeons changed a decision, the average discordance between the line of demarcation in white light imaging and advanced visualization was 3.7&#x2009;cm, compared to 0.41&#x2009;cm ( p &#x2009;=&#x2009;0.01) for cases without decision changes. There was no statistical difference between the line of ischemic demarcation using laser speckle versus indocyanine green ( p &#x2009;=&#x2009;0.16). Laser speckle quantified lower perfusion values for tissues beyond the line of ischemic demarcation while suggesting an additional 1&#x2009;cm of perfused tissue beyond this line. One (2.5%) anastomotic leak occurred in the intervention group.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was not powered to detect differences in anastomotic leak rates.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Advanced visualization using laser speckle and indocyanine green provides valuable perfusion information that impacts surgical decision-making in minimally invasive left-sided colorectal surgeries. See Video Abstract .</AbstractText><AbstractText Label="UTILIDAD CLNICA DE LAS IMGENES DE CONTRASTE MOTEADO CON LSER Y LA CUANTIFICACIN EN TIEMPO REAL DE LA PERFUSIN INTESTINAL EN RESECCIONES COLORRECTALES DEL LADO IZQUIERDO MNIMAMENTE INVASIVAS" NlmCategory="UNASSIGNED">ANTECEDENTES:La cirug&#xed;a colorrectal del lado izquierdo demuestra altas tasas de fuga anastom&#xf3;tica, y se cree que la isquemia tisular influye en los resultados. El verde de indocianina se utiliza habitualmente para evaluar la perfusi&#xf3;n, pero la evidencia sobre si reduce las fugas anastom&#xf3;ticas colorrectales sigue siendo contradictoria. Las im&#xe1;genes de contraste moteado con l&#xe1;ser proporcionan una evaluaci&#xf3;n de la perfusi&#xf3;n sin colorantes en tiempo real a trav&#xe9;s de mapas de calor de perfusi&#xf3;n y cuantificaci&#xf3;n.OBJETIVO:Este estudio investiga la eficacia de la evaluaci&#xf3;n de la perfusi&#xf3;n mediante visualizaci&#xf3;n avanzada (verde de indocianina versus im&#xe1;genes de contraste moteado con l&#xe1;ser) y la utilidad de la cuantificaci&#xf3;n de la perfusi&#xf3;n con moteado l&#xe1;ser para determinar los m&#xe1;rgenes isqu&#xe9;micos.DISE&#xd1;O:Grupo de intervenci&#xf3;n prospectivo que utiliza visualizaci&#xf3;n avanzada con un grupo de control retrospectivo de casos emparejados.LUGARES:Centro m&#xe9;dico acad&#xe9;mico &#xfa;nico.PACIENTES:Cuarenta pacientes adultos sometidos a cirug&#xed;a colorrectal electiva, m&#xed;nimamente invasiva, del lado izquierdo.INTERVENCIONES:Evaluaci&#xf3;n de la perfusi&#xf3;n intraoperatoria mediante im&#xe1;genes con luz blanca y visualizaci&#xf3;n avanzada en tres puntos temporales: T1-colon proximal despu&#xe9;s de la devascularizaci&#xf3;n, antes de la transecci&#xf3;n; T2-colon proximal/distal antes de la anastomosis; y T3-anastomosis completa.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:Indicaci&#xf3;n intraoperatoria de la l&#xed;nea de demarcaci&#xf3;n isqu&#xe9;mica antes de la resecci&#xf3;n bajo cada m&#xe9;todo de visualizaci&#xf3;n, cambio de decisi&#xf3;n quir&#xfa;rgica mediante visualizaci&#xf3;n avanzada, cuantificaci&#xf3;n post-hoc de la perfusi&#xf3;n con l&#xe1;ser moteado del tejido colorrectal y resultados posoperatorios a los 30 d&#xed;as.RESULTADOS:La visualizaci&#xf3;n avanzada cambi&#xf3; la toma de decisiones quir&#xfa;rgicas en el 17,5% de los casos. Para los casos en los que los cirujanos cambiaron una decisi&#xf3;n, la discordancia promedio entre la l&#xed;nea de demarcaci&#xf3;n en las im&#xe1;genes con luz blanca y la visualizaci&#xf3;n avanzada fue de 3,7 cm, en comparaci&#xf3;n con 0,41 cm (p = 0,01) para los casos sin cambios de decisi&#xf3;n. No hubo diferencias estad&#xed;sticas entre la l&#xed;nea de demarcaci&#xf3;n isqu&#xe9;mica utilizando l&#xe1;ser moteado versus verde de indocianina (p = 0,16). El moteado con l&#xe1;ser cuantific&#xf3; valores de perfusi&#xf3;n m&#xe1;s bajos para los tejidos m&#xe1;s all&#xe1; de la l&#xed;nea de demarcaci&#xf3;n isqu&#xe9;mica y al mismo tiempo sugiri&#xf3; 1 cm adicional de tejido perfundido m&#xe1;s all&#xe1; de esta l&#xed;nea. Se produjo una fuga anastom&#xf3;tica (2,5%) en el grupo de intervenci&#xf3;n.LIMITACIONES:Este estudio no tuvo el poder estad&#xed;stico suficiente para detectar diferencias en las tasas de fuga anastom&#xf3;tica.CONCLUSIONES:La visualizaci&#xf3;n avanzada utilizando moteado l&#xe1;ser y verde de indocianina proporciona informaci&#xf3;n valiosa sobre la perfusi&#xf3;n que impacta la toma de decisiones quir&#xfa;rgicas en cirug&#xed;as colorrectales m&#xed;nimamente invasivas del lado izquierdo. (Traducci&#xf3;n-Dr. Ingrid Melo).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skinner</LastName><ForeName>Garrett C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Jacobs School of Medicine and Biochemical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Activ Surgical, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yao Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Activ Surgical, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, The Warren Alpert Medical School, Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harzman</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Syed G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasior</LastName><ForeName>Alessandra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traugott</LastName><ForeName>Amber L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCulloh</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Activ Surgical, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalady</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Activ Surgical, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, The Warren Alpert Medical School, Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Emily S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Activ Surgical</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IX6J1063HV</RegistryNumber><NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007208" MajorTopicYN="Y">Indocyanine Green</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="Y">Anastomotic Leak</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081982" MajorTopicYN="Y">Laser Speckle Contrast Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38408871</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003098</ArticleId><ArticleId IdType="pii">00003453-202406000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guillou PJ, Quirke P, Thorpe H, et al.; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718&#x2013;1726.</Citation></Reference><Reference><Citation>Kang CY, Halabi WJ, Chaudhry OO, et al. Risk factors for anastomotic leakage after anterior resection for rectal cancer. JAMA Surg. 2013;148:65&#x2013;71.</Citation></Reference><Reference><Citation>Stamos MJ, Brady MT. Anastomotic leak: are we closer to eliminating its occurrence? Ann Laparosc Endosc Surg. 2018;3:66.</Citation></Reference><Reference><Citation>Buchs NC, Gervaz P, Secic M, Bucher P, Mugnier-Konrad B, Morel P. Incidence, consequences, and risk factors for anastomotic dehiscence after colorectal surgery: a prospective monocentric study. Int J Colorectal Dis. 2008;23:265&#x2013;270.</Citation></Reference><Reference><Citation>Lee SW, Gregory D, Cool CL. Clinical and economic burden of colorectal and bariatric anastomotic leaks. Surg Endosc. 2020;34:4374&#x2013;4381.</Citation></Reference><Reference><Citation>Hammond J, Lim S, Wan Y, Gao X, Patkar A. The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes. J Gastrointest Surg. 2014;18:1176&#x2013;1185.</Citation></Reference><Reference><Citation>Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253:890&#x2013;899.</Citation></Reference><Reference><Citation>Kulu Y, Tarantio I, Warschkow R, et al. Anastomotic leakage is associated with impaired overall and disease-free survival after curative rectal cancer resection: a propensity score analysis. Ann Surg Oncol. 2015;22:2059&#x2013;2067.</Citation></Reference><Reference><Citation>Vignali A, Gianotti L, Braga M, Radaelli G, Malvezzi L, Di Carlo V. Altered microperfusion at the rectal stump is predictive for rectal anastomotic leak. Dis Colon Rectum. 2000;43:76&#x2013;82.</Citation></Reference><Reference><Citation>Zarnescu EC, Zarnescu NO, Costea R. Updates of risk factors for anastomotic leakage after colorectal surgery. Diagnostics (Basel). 2021;11:2382.</Citation></Reference><Reference><Citation>Karliczek A, Benaron DA, Baas PC, Zeebregts CJ, Wiggers T, van Dam GM. Intraoperative assessment of microperfusion with visible light spectroscopy for prediction of anastomotic leakage in colorectal anastomoses. Colorectal Dis. 2010;12:1018&#x2013;1025.</Citation></Reference><Reference><Citation>Jafari MD, Wexner SD, Martz JE, et al. Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional study. J Am Coll Surg. 2015;220:82&#x2013;92.e1.</Citation></Reference><Reference><Citation>Clancy NT, Soares AS, Bano S, Lovat LB, Chand M, Stoyanov D. Intraoperative colon perfusion assessment using multispectral imaging. Biomed Opt Express. 2021;12:7556&#x2013;7567.</Citation></Reference><Reference><Citation>Mehdorn M, K&#xf6;hler H, Rabe SM, et al. Hyperspectral imaging (HSI) in acute mesenteric ischemia to detect intestinal perfusion deficits. J Surg Res. 2020;254:7&#x2013;15.</Citation></Reference><Reference><Citation>Briers JD. Laser Doppler, speckle and related techniques for blood perfusion mapping and imaging. Physiol Meas. 2001;22:R35&#x2013;R66.</Citation></Reference><Reference><Citation>Arezzo A, Bonino MA, Ris F, et al. Intraoperative use of fluorescence with indocyanine green reduces anastomotic leak rates in rectal cancer surgery: an individual participant data analysis. Surg Endosc. 2020;34:4281&#x2013;4290.</Citation></Reference><Reference><Citation>Jafari MD, Pigazzi A, McLemore EC, et al. Perfusion assessment in left-sided/low anterior resection (PILLAR III): a randomized, controlled, parallel, multicenter study assessing perfusion outcomes with PINPOINT near-infrared fluorescence imaging in low anterior resection. Dis Colon Rectum. 2021;64:995&#x2013;1002.</Citation></Reference><Reference><Citation>Spota A, Al-Taher M, Felli E, et al. Fluorescence-based bowel anastomosis perfusion evaluation: results from the IHU-IRCAD-EAES EURO-FIGS registry. Surg Endosc. 2021;35:7142&#x2013;7153.</Citation></Reference><Reference><Citation>Watanabe J, Takemasa I, Kotake M, et al. Blood perfusion assessment by indocyanine green fluorescence imaging for minimally invasive rectal cancer surgery (EssentiAL trial): a randomized clinical trial. Ann Surg. 2023;278.</Citation></Reference><Reference><Citation>Cassinotti E, Boni L, Della Porta M, Baldari L. The role of indocyanine green performing a minimally invasive right colectomy. Ann Laparosc Endosc Surg. 2021;6:30&#x2013;30.</Citation></Reference><Reference><Citation>Towle EL, Richards LM, Kazmi SMS, Fox DJ, Dunn AK. Comparison of indocyanine green angiography and laser speckle contrast imaging for the assessment of vasculature perfusion. Neurosurgery. 2012;71:1023&#x2013;1030.</Citation></Reference><Reference><Citation>Dupr&#xe9;e A, Rie&#xdf; H, Detter C, Debus ES, Wipper SH. Utilization of indocynanine green fluorescent imaging (ICG-FI) for the assessment of microperfusion in vascular medicine. Innov Surg Sci. 2018;3:193&#x2013;201.</Citation></Reference><Reference><Citation>Nwaiwu CA, Buharin VE, Mach A, et al. Feasibility and comparison of laparoscopic laser speckle contrast imaging to near-infrared display of indocyanine green in intraoperative tissue blood flow/tissue perfusion and extrahepatic bile ducts in preclinical porcine models. J Am Coll Surg. 2021;233:S78&#x2013;S79.</Citation></Reference><Reference><Citation>Kojima S, Sakamoto T, Nagai Y, Matsui Y, Nambu K, Masamune K. Laser speckle contrast imaging for intraoperative quantitative assessment of intestinal blood perfusion during colorectal surgery: a prospective pilot study. Surg Innov. 2019;26:293&#x2013;301.</Citation></Reference><Reference><Citation>Heeman W, Steenbergen W, van Dam G, Boerma EC. Clinical applications of laser speckle contrast imaging: a review. J Biomed Opt. 2019;24:1&#x2013;11.</Citation></Reference><Reference><Citation>Draijer M, Hondebrink E, van Leeuwen T, Steenbergen W. Review of laser speckle contrast techniques for visualizing tissue perfusion. Lasers Med Sci. 2009;24:639&#x2013;651.</Citation></Reference><Reference><Citation>Bagiella E, Chang H. Power analysis and sample size calculation. J Mol Cell Cardiol. 2019;133:214&#x2013;216.</Citation></Reference><Reference><Citation>Shah SK, Nwaiwu CA, Agarwal A, et al. First-in-human (FIH) safety, feasibility, and usability trial of a laparoscopic imaging device using laser speckle contrast imaging (LSCI) visualizing real-time tissue perfusion and blood flow without fluorophore in colorectal and bariatric patients. J Am Coll Surg. 2021;233:S45&#x2013;S46.</Citation></Reference><Reference><Citation>Garoufalia Z, Wexner SD. Indocyanine green fluorescence guided surgery in colorectal surgery. J Clin Med. 2023;12:494.</Citation></Reference><Reference><Citation>Goncalves LN, van den Hoven P, van Schaik J, et al. Perfusion parameters in near-infrared fluorescence imaging with indocyanine green: a systematic review of the literature. Life (Basel). 2021;11:433.</Citation></Reference><Reference><Citation>Mascagni P, Alapatt D, Sestini L, et al. Computer vision in surgery: from potential to clinical value. NPJ Digit Med. 2022;5:163.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36870524</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6500</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of shoulder and elbow surgery</Title><ISOAbbreviation>J Shoulder Elbow Surg</ISOAbbreviation></Journal><ArticleTitle>The Spanish version of the Constant-Murley Shoulder Score: translation, cultural adaptation, and validity.</ArticleTitle><Pagination><StartPage>1348</StartPage><EndPage>1356</EndPage><MedlinePgn>1348-1356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jse.2023.01.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1058-2746(23)00129-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Constant-Murley Score (CMS) is one of the most employed tools for assessing shoulder function. It was first devised in 1987 for the English population and is now widely used internationally. However, it had yet to be cross-culturally adapted and validated to Spanish, which is the world's second-most native language. Formal adaptation and validation of clinical scores is paramount for them to be used with rigorous scientific methodology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following international recommendations for the cross-cultural adaptation of self-report measures, the CMS was first adapted into Spanish in six stages: translation, synthesis, back-translation, a review by expert committee, pretesting, and final appraisal by expert committee. After conducting a pretest with 30 individuals, the Spanish version of the CMS was tested on 104 patients with various shoulder pathologies to assess content, construct, criterion validity, and reliability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No major conflicts were encountered in the process of cross-cultural adaptation, with 96.7% of pretested patients having a full understanding of every item in the test. The validation showed excellent content validity (content validity index&#xa0;=&#xa0;.90), construct validity (strong correlation between items within the same subsection of the test), and criterion validity (CMS - Simple Shoulder Test, Pearson r&#xa0;=&#xa0;.587, P&#xa0;=&#xa0;.01; CMS - American Shoulder and Elbow Surgeons, Pearson r&#xa0;=&#xa0;.690, P&#xa0;=&#xa0;.01). Reliability of the test was also excellent, with high internal consistency (Cronbach's &#x3b1;&#xa0;=&#xa0;.819), interrater reliability (intraclass correlation coefficient =&#xa0;.982), and intrarater reliability (intraclass correlation coefficient =&#xa0;.937), without showing ceiling or floor effects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Spanish version of the CMS has been proved to accurately reproduce the original score and to be easily comprehensible by native Spanish speakers with acceptable intrarater-interrater reliability and construct validity. INTRODUCCI&#xf3;N: La escala de Constant-Murley (CMS) es una de las m&#xe1;s empleadas para evaluar la funci&#xf3;n del hombro. Se ide&#xf3; por primera vez para la poblaci&#xf3;n inglesa en 1987 y actualmente es ampliamente empleada a nivel internacional. Sin embargo, su validaci&#xf3;n y adaptaci&#xf3;n transcultural no se han realizado al espa&#xf1;ol, la segunda lengua nativa m&#xe1;s hablada en el mundo. Actualmente no puede resultar admisible el empleo de escalas en las que no tengamos la seguridad de que existe una equivalencia conceptual, cultural y ling&#xfc;&#xed;stica entre la versi&#xf3;n original y la empleada. MATERIAL Y M&#xe9;TODO: La versi&#xf3;n traducida al espa&#xf1;ol de la CMS se realiz&#xf3; siguiendo las recomendaciones internacionales: traducci&#xf3;n, s&#xed;ntesis de la traducci&#xf3;n, retrotraducci&#xf3;n, revisi&#xf3;n por comit&#xe9; de expertos, pretest y validaci&#xf3;n. Tras la realizaci&#xf3;n del pretest en 30 individuos, la versi&#xf3;n espa&#xf1;ola de la escala de CMS se prob&#xf3; en 104 pacientes con diferentes patolog&#xed;as de hombro para evaluar las propiedades psicom&#xe9;tricas de la escala: contenido, constructo, validez de criterio y fiabilidad.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">No se encontraron problemas importantes durante el proceso de adaptaci&#xf3;n transultural con un entendimiento completo de todos los &#xed;tems del pretest por el 96.7% de los pacientes. La escala adaptada demostr&#xf3; una excelente validez de contenido (&#xed;ndice de validez&#xa0;de contenido&#xa0;=&#xa0;.90), de constructo (fuerte correlaci&#xf3;n entre &#xed;tems de la misma subsecci&#xf3;n del test), y de criterio (CMS-SST Pearson's r&#xa0;=&#xa0;.587, p&#xa0;=&#xa0;.01; CMS-ASES Pearson's r&#xa0;=&#xa0;.690, p&#xa0;=&#xa0;.01). La Fiabilidad del test result&#xf3; excelente, con una elevada consistencia interna (Cronbach's &#x3b1;&#xa0;=&#xa0;.819), fiabilidad interobservador (ICC&#xa0;=&#xa0;.982) e intraobservador (ICC&#xa0;=&#xa0;.937), sin efectos techo y suelo. CONCLUSI&#xf3;N: La versi&#xf3;n Espa&#xf1;ola de la CMS garantiza la equivalencia con respecto al cuestionario original. Los presentes resultados, sugieren que esta versi&#xf3;n es v&#xe1;lida, fiable y reproducible para la evaluaci&#xf3;n de la patolog&#xed;a de hombro en nuestro entorno.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopiz</LastName><ForeName>Yaiza</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain; Department of Surgery, Complutense University, Madrid, Spain. Electronic address: yaizalopiz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garr&#xed;guez-P&#xe9;rez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarano-Pereira</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes Ferrer</LastName><ForeName>Manuel E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Clinical Trials and Research Unit, Preventive Medicine Department, Cl&#xed;nico San Carlos Hospital, IdISSC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arvinius</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponz</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Fern&#xe1;ndez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Department of Traumatology and Orthopaedic Surgery, Cl&#xed;nico San Carlos Hospital, Madrid, Spain; Department of Surgery, Complutense University, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Shoulder Elbow Surg</MedlineTA><NlmUniqueID>9206499</NlmUniqueID><ISSNLinking>1058-2746</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012782" MajorTopicYN="Y">Shoulder</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014177" MajorTopicYN="Y">Translations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Constant score</Keyword><Keyword MajorTopicYN="N">Constant-Murley Score</Keyword><Keyword MajorTopicYN="N">Spanish</Keyword><Keyword MajorTopicYN="N">reliability</Keyword><Keyword MajorTopicYN="N">shoulder function</Keyword><Keyword MajorTopicYN="N">validity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>19</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36870524</ArticleId><ArticleId IdType="doi">10.1016/j.jse.2023.01.032</ArticleId><ArticleId IdType="pii">S1058-2746(23)00129-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36268647</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-9767</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Global health promotion</Title><ISOAbbreviation>Glob Health Promot</ISOAbbreviation></Journal><ArticleTitle>Soberan&#xed;a alimentaria y salud: perspectivas de tres pueblos ind&#xed;genas de Colombia.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>94</EndPage><MedlinePgn>86-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17579759221113492</ELocationID><Abstract><AbstractText Label="RESUMEN" NlmCategory="UNASSIGNED">La soberan&#xed;a alimentaria es el derecho colectivo a decidir sobre la producci&#xf3;n, distribuci&#xf3;n y consumo de alimentos y promueve la generaci&#xf3;n de suministros alimenticios para el consumo local de tal forma que los consumidores queden resguardados de la volatilidad de los precios de mercados internacionales. En los pueblos ind&#xed;genas esta tendencia resulta trascendental para hacer frente a condiciones de inequidad hist&#xf3;rica que han impactado negativamente su salud p&#xfa;blica. No obstante, es ignorada en algunos casos y en otros reemplazada por nociones centradas en la seguridad alimentaria, t&#xe9;rmino alineado con pol&#xed;ticas transnacionales derivadas del modelo econ&#xf3;mico dominante.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">analizar con tres comunidades ind&#xed;genas de Colombia las perspectivas de soberan&#xed;a alimentaria y su influencia en la salud.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">investigaci&#xf3;n participativa basada en la comunidad, para recolectar datos mediante grupos de discusi&#xf3;n, entrevistas y observaci&#xf3;n. La poblaci&#xf3;n de estudio fueron tres comunidades ind&#xed;genas del sur de Colombia. La selecci&#xf3;n de participantes se realiz&#xf3; seg&#xfa;n su trayectoria en la comunidad.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">las comunidades entienden la soberan&#xed;a alimentaria como la conservaci&#xf3;n de semillas nativas y alimentos propios, vista como oportunidad para el cuidado de la salud. Su debilitamiento se relaciona con el desarrollo de enfermedades de las personas y de la madre tierra. Para su fortalecimiento identificaron el tul, el yatul y la chagra (huerta) que reafirman la uni&#xf3;n familiar, contribuyen a la recuperaci&#xf3;n de modos de producci&#xf3;n desde la sabidur&#xed;a ancestral y se posicionan como alternativa para la sostenibilidad econ&#xf3;mica.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">la soberan&#xed;a alimentaria conserva los saberes y pr&#xe1;cticas tradicionales para una alimentaci&#xf3;n propia, debilitada por los sistemas agroindustriales. Es asumida como iniciativa local suscrita en un proyecto global de resistencia pol&#xed;tica y econ&#xf3;mica para la salud colectiva de los pueblos.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calder&#xf3;n Farf&#xe1;n</LastName><ForeName>Juan Camilo</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-5965-5771</Identifier><AffiliationInfo><Affiliation>Doctorado en Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Enfermer&#xed;a, Universidad Surcolombiana, Neiva, Huila, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosero Medina</LastName><ForeName>Diego Fernando</ForeName><Initials>DF</Initials><Identifier Source="ORCID">0000-0002-4676-655X</Identifier><AffiliationInfo><Affiliation>Programa de Enfermer&#xed;a, Universidad Surcolombiana, Neiva, Huila, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arias Torres</LastName><ForeName>Dolly</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Doctorado en Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Enfermer&#xed;a, Universidad Surcolombiana, Neiva, Huila, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Glob Health Promot</MedlineTA><NlmUniqueID>101497462</NlmUniqueID><ISSNLinking>1757-9759</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="Y">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">investigaci&#xf3;n comunitaria / investigaci&#xf3;n participativa</Keyword><Keyword MajorTopicYN="N">salud ind&#xed;gena</Keyword><Keyword MajorTopicYN="N">salud p&#xfa;blica</Keyword><Keyword MajorTopicYN="N">seguridad alimentaria</Keyword><Keyword MajorTopicYN="N">soberan&#xed;a alimentaria</Keyword></KeywordList><CoiStatement>Ning&#xfa;n conflicto declarado por parte de los autores.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36268647</ArticleId><ArticleId IdType="pmc">PMC10273856</ArticleId><ArticleId IdType="doi">10.1177/17579759221113492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FAO, Departamento para la Prosperidad Social. Comida, territorio y memoria. Situaci&#xf3;n alimentaria de los pueblos ind&#xed;genas colombianos [Internet]. Bogot&#xe1;: FAO. 2015, pp. 1&#x2013;118 [citado el 21 de abril de 2020]. Disponible en: http://www.fao.org/3/a-i4467s.pdf</Citation></Reference><Reference><Citation>L&#xf3;pez-Giraldo LA, Franco-Giraldo &#xc1;. Revisi&#xf3;n de enfoques de pol&#xed;ticas alimentarias: entre la seguridad y la soberan&#xed;a alimentaria (2000-2013). Cad Saude Publica. 2015; 31: 1355&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">26248092</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MS. Still searching for (food) sovereignty: why are radical discourses only partially mobilised in the independent Anglo-Caribbean? Geoforum. 2019; 101: 90&#x2013;99.</Citation></Reference><Reference><Citation>Rocha C, Liberato RS. Food sovereignty for cultural food security: the case of an indigenous community in Brazil. Food Cult Soc. 2013; 16: 589&#x2013;602.</Citation></Reference><Reference><Citation>Meyer MA. Hoea Ea: land education and food sovereignty in Hawaii. Environ Educ Res. 2014; 20: 98&#x2013;101.</Citation></Reference><Reference><Citation>Weiler AM, Hergesheimer C, Brisbois B, Wittman H, Yassi A, Spiegel JM. Food sovereignty, food security and health equity: a meta-narrative mapping exercise. Health Policy Plan. 2015; 30: 1078&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559116</ArticleId><ArticleId IdType="pubmed">25288515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke S, Delormier T. Indigenous Peoples&#x2019; food systems, nutrition, and gender: conceptual and methodological considerations. Matern Child Nutr. 2017; 13: e12499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866027</ArticleId><ArticleId IdType="pubmed">29359433</ArticleId></ArticleIdList></Reference><Reference><Citation>Duthie-Kannikkatt K, Shukla S, Rao MLS, Sakkhari K, Pachari D. Sowing the seeds of resilience: a case study of community-based indigenous seed conservation from Andhra Pradesh, India. Local Environ. 2019; 24: 843&#x2013;860.</Citation></Reference><Reference><Citation>Sergio C, Garces M, Peters K. Psicolog&#xed;a comunitaria y salud ind&#xed;gena en la Amazonia: La experiencia del Proyecto Chat&#xe3;ee. Revista De Ciencias Sociales. 2012; 25: 112&#x2013;129.</Citation></Reference><Reference><Citation>Israel BA, Coombe CM, Cheezum RR, Schulz AJ, McGranaghan RJ, Lichtenstein R, et al.. Community-based participatory research: a capacity-building approach for policy advocacy aimed at eliminating health disparities. Am J Public Health. 2010; 100: 2094&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951933</ArticleId><ArticleId IdType="pubmed">20864728</ArticleId></ArticleIdList></Reference><Reference><Citation>Organizaci&#xf3;n Nacional Ind&#xed;gena de Colombia. Pueblos Ind&#xed;genas [Internet]. ONIC;2020.  [citado el 23 de abril del 2020]. Disponible en: https://www.onic.org.co/pueblos/2095-nasa</Citation></Reference><Reference><Citation>Hurtado ME, Sanabria Cant&#xf3;n JN. Documento diagn&#xf3;stico diferencial del Resguardo Nuevo Amanecer de la etnia Misak en La Argentina Huila. [Internet]. Bogot&#xe1;: Convenio Interadministrativo No. 263 de 2017 suscrito entre la Naci&#xf3;n &#x2013; Ministerio de Comercio, Industria y Turismo y Artesan&#xed;as de Colombia, S.A; 2017.  [citado el 18 de abril de 2020]. Disponible en: https://repositorio.artesaniasdecolombia.com.co/bitstream/001/4175/1/INST-D%202017.%2077.pdf</Citation></Reference><Reference><Citation>Departamento Administrativo Nacional de Estad&#xed;stica. Colombia Una Naci&#xf3;n Multicultural; Poblaci&#xf3;n &#xc9;tnica y Censo General 2005. [Internet]. 2007. [citado el 20 de marzo del 2018]. Disponible en: https://www.dane.gov.co/files/censo2005/etnia/sys/colombia_nacion.pdf</Citation></Reference><Reference><Citation>Strauss A, Corbin J. Bases de la investigaci&#xf3;n cualitativa:t&#xe9;cnicas y procedimientos para desarrollar la teor&#xed;a fundamentada. Universidad de Antioquia; 2002, p.374 [citado el 18 de abril de 2020]. Disponible en: https://diversidadlocal.files.wordpress.com/2012/09/bases-investigacion-cualitativa.pdf</Citation></Reference><Reference><Citation>Calder&#xf3;n Farf&#xe1;n JC, Torres Soto MA, Quintero Montoya V, Cruz Rodr&#xed;guez L, Gonz&#xe1;lez Cer&#xf3;n J, Vargas Guadarrama A, et al.. Practices of food autonomy in the nasa indigenous cosmovision in Colombia. Agroecol Sustain Food Syst. 2021; 45: 1&#x2013;17.</Citation></Reference><Reference><Citation>Kuhnlein HV. Food system sustainability for health and well-being of Indigenous Peoples. Public Health Nutr. 2015; 18: 2415&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10271446</ArticleId><ArticleId IdType="pubmed">25522932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad K, Pieroni A. Folk knowledge of wild food plants among the tribal communities of Thakht-e-Sulaiman Hills, North-West Pakistan. J Ethnobiol Ethnomed. 2016; 12: 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826518</ArticleId><ArticleId IdType="pubmed">27059025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray L, Burnett K, Cameron A, Joseph S, LeBlanc J, Parker B, et al.. Examining Indigenous food sovereignty as a conceptual framework for health in two urban communities in Northern Ontario, Canada. Glob Health Promot. 2019; 26(Suppl 3): 54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30964405</ArticleId></ArticleIdList></Reference><Reference><Citation>Huambachano M. Enacting food sovereignty in Aotearoa New Zealand and Peru: revitalizing Indigenous knowledge, food practices and ecological philosophies. Agroecol Sustainable Food Syst. 2018; 42: 1003&#x2013;1028.</Citation></Reference><Reference><Citation>Delormier T, Marquis K. Building healthy community relationships through food security and food sovereignty. Curr Dev Nutr. 2019; 3(Suppl 2): 25&#x2013;31.</Citation></Reference><Reference><Citation>Chat&#xe9; Tumi&#xf1;&#xe1; R. Plan estrat&#xe9;gico para fortalecer la soberan&#xed;a alimentaria, y el respeto integral de la madre tierra en el Resguardo Ind&#xed;gena de Yaquiv&#xe1;, Inz&#xe1;, Cauca. Trabajo de grado de especializaci&#xf3;n (Especialista en Gerencia Educativa). Universidad Cat&#xf3;lica de Manizales, Facultad de Educaci&#xf3;n, 2013.  [citado el 23 de abril de 2020]. Disponible en: http://bibliotecavirtualoducal.uc.cl/vufind/Record/oai:localhost:10839-608</Citation></Reference><Reference><Citation>Sowerwine J, Mucioki M, Sarna-Wojcicki D, Hillman L. Reframing food security by and for Native American communities: a case study among tribes in the Klamath River basin of Oregon and California. Food Secur. 2019; 11: 579&#x2013;607.</Citation></Reference><Reference><Citation>Parraguez-Vergara E, Contreras B, Clavijo N, Villegas V, Paucar N, Ther F. Does indigenous and campesino traditional agriculture have anything to contribute to food sovereignty in Latin America? Evidence from Chile, Peru, Ecuador, Colombia, Guatemala and Mexico. Int J Agric Sustain. 2018; 16: 326&#x2013;341.</Citation></Reference><Reference><Citation>Rojas Gonz&#xe1;lez EW, Cifuentes &#xc1;lava DM, J&#xe1;come Bosquez IJ, Jij&#xf3;n S&#xe1;nchez EJ, Noguera Barrera ND. Pr&#xe1;cticas alimentarias en comunidades ind&#xed;genas y su salud. La Cienc al Serv la Salud y la Nutr. 2019; 10(Num. Especial Seminarios de Salud P&#xfa;blica): 362&#x2013;372.</Citation></Reference><Reference><Citation>Proyecto Apoyo a la Prevenci&#xf3;n de Desastres en la Comunidad Andina &#x2013; PREDECAN. Cosmovisi&#xf3;n del pueblo ind&#xed;gena Nasa en Colombia: Reducci&#xf3;n integral de los riesgos, planificaci&#xf3;n y desarrollo sostenible [Internet]. Per&#xfa;: Secretar&#xed;a General de la Comunidad Andina; 2009, pp.1&#x2013;36 [citado el 5 de abril de 2020]. Disponible en: http://www.comunidadandina.org/predecan/doc/libros/SISTE22/CO/CO_NASA.pdf</Citation></Reference><Reference><Citation>Longvah T, Khutsoh B, Meshram I, Krishna S, Kodali V, Roy P, et al.. Mother and child nutrition among the Chakhesang tribe in the state of Nagaland, North-East India. Matern Child Nutr. 2017; 13(Suppl 3): e12558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866219</ArticleId><ArticleId IdType="pubmed">29359431</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero Laverde MC, Torrado OP, Urrea C, Ospina O. La salud en la cosmovisi&#xf3;n de una comunidad ind&#xed;gena. Retos educativos con perspectiva intercultural. Rev Iberoam Eduaci&#xf3;n e Investig en Enfermer&#xed;a. 2012; 2: 10&#x2013;16.</Citation></Reference><Reference><Citation>DeBruyn L, Fullerton L, Satterfield D, Frank M. Integrating culture and history to promote health and help prevent type 2 diabetes in American Indian/Alaska Native communities: traditional foods have become a way to talk about health. Prev Chronic Dis. 2020; 17: 190213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7021459</ArticleId><ArticleId IdType="pubmed">32027813</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo A. Food policy in Peru: the debate of food sovereignty versus food security. In: Reference Module in Food Science. Elsevier; 2016, pp.1&#x2013;7 [citado el 15 de abril de 2020]. Disponible en: 10.1016/B978-0-08-100596-5.21045-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-08-100596-5.21045-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin R A, Maughan C, Pimbert MP. Aprendizaje agroecol&#xf3;gico transformador en Europa: Creaci&#xf3;n de conciencia, habilidades y capacidad colectiva para la soberan&#xed;a alimentaria. AE Rev Agroecol Divulg. 2019; 37: 54&#x2013;56.</Citation></Reference><Reference><Citation>Pimbert M. Food sovereignty and autonomous local systems. RCC Perspect. 2015; 1: 37&#x2013;43.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34990422</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management.</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>197</EndPage><MedlinePgn>189-197</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002281</ELocationID><Abstract><AbstractText Label="BACKGROUND">Anal adenocarcinoma is a rare clinical entity for which the optimal management is not defined.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to describe the multidisciplinary management and outcomes of patients with anal adenocarcinoma.</AbstractText><AbstractText Label="DESIGN">This is a retrospective cohort study.</AbstractText><AbstractText Label="SETTING">This study was conducted at a quaternary cancer center.</AbstractText><AbstractText Label="PATIENTS">Men and women with anal adenocarcinoma treated between 1995 and 2016 were selected.</AbstractText><AbstractText Label="INTERVENTIONS">Fifty-two patients were treated with either chemoradiotherapy or trimodality therapy including radiation therapy, chemotherapy, and surgical resection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Local failure, regional failure, and distant metastasis rates were estimated using the cumulative incidence method. The Kaplan-Meier method was used to estimate progression-free survival and overall survival. The multivariable Cox proportional hazards model was used to evaluate the clinical predictors of outcome.</AbstractText><AbstractText Label="RESULTS">There was a higher 5-year rate of local failure in patients treated with chemoradiotherapy compared with trimodality therapy (53% vs 10%; p &lt; 0.01). The 5-year incidence of distant metastases was 29% (trimodality therapy) versus 30% (chemoradiotherapy; p = 0.9); adjuvant chemotherapy did not reduce the incidence of distant metastases (p = 0.8). Five-year overall survival was 73% (trimodality therapy) versus 49.4% (chemoradiotherapy; p = 0.1). On multivariable analysis, factors associated with worse overall survival were treatment with chemoradiotherapy, cT3-4 category disease, and node-positive disease.</AbstractText><AbstractText Label="LIMITATIONS">This study is limited by its small sample size and retrospective nature.</AbstractText><AbstractText Label="CONCLUSIONS">Although treatment may continue to be tailored to individual patients, better outcomes with a trimodality therapy approach were observed. See Video Abstract at http://links.lww.com/DCR/B708.ADENOCARCINOMA ANAL: UNA ENTIDAD POCO FRECUENTE EN NECESIDAD DE UN MANEJO MULTIDISCIPLINARIO.</AbstractText><AbstractText Label="ANTECEDENTES">El adenocarcinoma anal es una entidad cl&#xed;nica poco frecuente por lo que a&#xfa;n no se define el manejo &#xf3;ptimo.</AbstractText><AbstractText Label="OBJETIVO">Describir el manejo multidisciplinario y los resultados de los pacientes con adenocarcinoma anal.</AbstractText><AbstractText Label="DISEO">Estudio de cohorte retrospectivo.</AbstractText><AbstractText Label="ENTORNO CLINICO">Centro de c&#xe1;ncer cuaternario.</AbstractText><AbstractText Label="PACIENTES">Hombres y mujeres con adenocarcinoma anal tratados entre 1995 y 2016.</AbstractText><AbstractText Label="INTERVENCIONES">Cincuenta y dos pacientes fueron tratados con quimiorradioterapia o terapia trimodal que incluy&#xf3;: radioterapia, quimioterapia y resecci&#xf3;n quir&#xfa;rgica.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE VALORACION">Se estimaron las tasas de falla local, falla regional y met&#xe1;stasis a distancia mediante el m&#xe9;todo de incidencia acumulada. Se utiliz&#xf3; el m&#xe9;todo de Kaplan-Meier para estimar la supervivencia libre de progresi&#xf3;n y la supervivencia global. Los riesgos proporcionales de multivariable Cox se utilizaron para evaluar los predictores cl&#xed;nicos de los resultados.</AbstractText><AbstractText Label="RESULTADOS">Hubo una mayor tasa de falla local a cinco a&#xf1;os en pacientes tratados con quimiorradioterapia en comparaci&#xf3;n con terapia trimodal (53% vs 10%; p &lt; 0,01). La incidencia a cinco a&#xf1;os de met&#xe1;stasis a distancia fue del 29% (terapia trimodal) versus 30% (quimiorradioterapia) (p = 0,9); la quimioterapia adyuvante no redujo la incidencia de met&#xe1;stasis a distancia (p = 0,8). La supervivencia global a cinco a&#xf1;os fue del 73% (terapia trimodal) versus 49,4% (quimiorradioterapia); p = 0,1. En el an&#xe1;lisis multivariable, los factores asociados con una peor supervivencia general fueron el tratamiento con quimiorradioterapia, enfermedad de categor&#xed;a cT3-4 y enfermedad con ganglios positivos.</AbstractText><AbstractText Label="LIMITACIONES">Este estudio est&#xe1; limitado por su peque&#xf1;o tama&#xf1;o de muestra y su naturaleza retrospectiva.</AbstractText><AbstractText Label="CONCLUSIONES">Aunque el tratamiento puede seguir adapt&#xe1;ndose a pacientes individuales, se observaron mejores resultados con un enfoque TTM. Conslute Video Resumen en http://links.lww.com/DCR/B708. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lukovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>J John</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhihui Amy</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brierley</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Rebecca K S</ForeName><Initials>RKS</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringash</LastName><ForeName>Jolie G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Aisling</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krzyzanowska</LastName><ForeName>Monika K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Eric X</ForeName><Initials>EX</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedley</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quereshy</LastName><ForeName>Fayez A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swallow</LastName><ForeName>Carol J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gryfe</LastName><ForeName>Robert N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Erin D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Easson</LastName><ForeName>Alexandra M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosni</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>17</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34990422</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002281</ArticleId><ArticleId IdType="pii">00003453-202202000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cabrera A, Tsukada Y, Pickren JW. Adenocarcinomas of the anal canal and peri-anal tissues. Ann Surg. 1966;164:152&#x2013;156.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7&#x2013;30.</Citation></Reference><Reference><Citation>Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27&#x2013;33.</Citation></Reference><Reference><Citation>Hosni A, Han K, Le LW, et al. The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. Oncotarget. 2018;9:20439&#x2013;20450.</Citation></Reference><Reference><Citation>Belkac&#xe9;mi Y, Berger C, Poortmans P, et al.; Rare Cancer Network. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2003;56:1274&#x2013;1283.</Citation></Reference><Reference><Citation>Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009;52:1375&#x2013;1380.</Citation></Reference><Reference><Citation>Kounalakis N, Artinyan A, Smith D, Mojica-Manoso P, Paz B, Lai LL. Abdominal perineal resection improves survival for nonmetastatic adenocarcinoma of the anal canal. Ann Surg Oncol. 2009;16:1310&#x2013;1315.</Citation></Reference><Reference><Citation>Wegner RE, White RJ, Hasan S, et al. Anal adenocarcinoma: treatment outcomes and trends in a rare disease entity. Cancer Med. 2019;8:3855&#x2013;3863.</Citation></Reference><Reference><Citation>Lewis GD, Haque W, Butler EB, Teh BS. Survival outcomes and patterns of management for anal adenocarcinoma. Ann Surg Oncol. 2019;26:1351&#x2013;1357.</Citation></Reference><Reference><Citation>Han K, Cummings BJ, Lindsay P, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90:587&#x2013;594.</Citation></Reference><Reference><Citation>Papagikos M, Crane CH, Skibber J, et al. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys. 2003;55:669&#x2013;678.</Citation></Reference><Reference><Citation>. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465&#x2013;1472.</Citation></Reference><Reference><Citation>Cedermark B, Dahlberg M, Glimelius B, P&#xe5;hlman L, Rutqvist LE, Wilking N; . Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980&#x2013;987.</Citation></Reference><Reference><Citation>Camm&#xe0; C, Giunta M, Fiorica F, Pagliaro L, Crax&#xec; A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008&#x2013;1015.</Citation></Reference><Reference><Citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638&#x2013;646.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174&#x2013;183.</Citation></Reference><Reference><Citation>O&#x2019;Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246&#x2013;250.</Citation></Reference><Reference><Citation>Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905&#x2013;914.</Citation></Reference><Reference><Citation>Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509&#x2013;2520.</Citation></Reference><Reference><Citation>Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28:3485&#x2013;3490.</Citation></Reference><Reference><Citation>Amin MB, Edge S, Greene F, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017.</Citation></Reference><Reference><Citation>Brierley JD, Gospodarowicz MK, Wittekind C, eds. The TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley Blackwell; 2017.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>